ArticleInvestigative radiology2018
Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis.
Article in Investigative radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Rationales for Non-standard GBCA Dosing-Low?-High?-When? and Why?: A Literature-based Study.Investigative radiology · 2026Pooled it
- Population arterial input function measured from low dose breast ultrafast dynamic contrast enhanced MRI and fitted with a new mathematic model.Magnetic resonance imaging · 2026Article
- A deep learning model to reduce agent dose for contrast-enhanced MRI of the cerebellopontine angle cistern.European radiology · 2026Article
- Low-dose GBCA administration for brain tumour dynamic contrast enhanced MRI: a feasibility study.Scientific reports · 2024Article
- Review of strategies to reduce the contamination of the water environment by gadolinium-based contrast agents.Insights into imaging · 2024Review
- Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy.Cancers · 2023Article
- Magnetic resonance imaging contrast enhancement synthesis using cascade networks with local supervision.Medical physics · 2022Article
- Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study.European radiology · 2022Article
- New prostate MRI techniques and sequences.Abdominal radiology (New York) · 2020Review
- Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI.Tomography (Ann Arbor, Mich.) · 2019Article
- Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol.Clinical imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesThis study investigates whether administration of low doses of gadolinium-based contrast agent (GBCA) for dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can be as effective as a standard dose in distinguishing prostate cancer (PCa) from benign tissue. In addition, we evaluated the combination of kinetic parameters from the low- and high-dose injection as a new diagnostic marker. MATERIALS AND
methodsPatients (n = 17) with histologically confirmed PCa underwent preoperative 3 T MRI. Dynamic contrast-enhanced MRI images were acquired at 8.3-second temporal resolution with a low dose (0.015 mmol/kg) and close to the standard dose (0.085 mmol/kg) of gadobentate dimeglumine bolus injections. Low-dose images were acquired for 3.5 minutes, followed by a 5-minute gap before acquiring standard dose images for 8.3 minutes. The data were analyzed qualitatively to investigate whether lesions could be detected based on early focal enhancement and quantitatively by fitting signal intensity as a function of time with an empirical mathematical model to obtain a maximum enhancement projection (MEP) and signal enhancement rate (α).
resultsBoth low- and standard-dose DCE-MRI showed similar sensitivity (13/26 = 50%) and lesion conspicuity score (4.0 ± 1.0 vs 4.2 ± 0.9; P = 0.317) for PCa diagnosis on qualitative analysis. Prostate cancer showed significantly increased α compared with benign tissue for low (9.98 ± 5.84 vs 5.12 ± 2.95 s) but not for standard (4.27 ± 2.20 vs 3.35 ± 1.48 s) dose. The ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and T2* effects associated with cancer. In addition, decreases in the percentage change in T1 relaxation rate as a function of increasing contrast media concentration (ie, the "saturation effect") can also contribute to the observed differences in high-dose and low-dose α. Area under the receiver operating characteristic curve for differentiating PCa from benign tissue using α was higher for low dose (0.769) compared with standard dose (0.625). There were no significant differences between MEP calculated for PCa and normal tissue at the low and standard doses. Moderate significant Pearson correlation for DCE parameters, MEP (r = 0.53) and α (r = 0.58), was found between low and standard doses of GBCA.
conclusionsThese preliminary results suggest that DCE-MRI with a low GBCA dose distinguishes PCa from benign prostate tissue more effectively than does the standard GBCA dose, based on signal enhancement rate. Diagnostic accuracy is similar on qualitative assessment. Prostate cancer diagnosis may be feasible with DCE-MRI with low-dose GBCA. In addition, comparison of enhancement kinetics after low and high doses of contrast media may provide diagnostically useful information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.